middl
east
respiratori
syndrom
coronaviru
merscov
detect
human
sinc
sporad
outbreak
primari
transmiss
dromedari
camel
human
outbreak
healthcar
set
shown
merscov
continu
pose
threat
human
health
sever
serolog
assay
merscov
develop
global
describ
collabor
studi
investig
compar
serolog
assay
merscov
assess
benefit
associ
introduct
standard
refer
reagent
merscov
serolog
studi
find
indic
possibl
laboratori
use
test
algorithm
includ
test
ensur
correct
diagnosi
merscov
also
demonstr
use
refer
reagent
greatli
improv
agreement
assay
enabl
consist
therefor
meaning
comparison
result
inc
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
laboratoryconfirm
case
report
world
health
organ
approxim
one
third
case
fatal
larg
proport
merscov
case
result
humantohuman
transmiss
healthcar
set
outbreak
occur
sever
countri
largest
outbreak
seen
saudi
arabia
unit
arab
emir
south
korea
dromedari
camel
put
reservoir
host
merscov
experi
mild
symptom
upon
infect
primari
infect
occur
dromedari
camel
human
new
case
evid
camel
contact
continu
occur
sporad
merscov
highthreat
pathogen
research
develop
blueprint
document
set
roadmap
research
develop
diagnost
prevent
therapeut
product
prevent
earli
detect
respons
highprior
pathogen
roadmap
merscov
list
sever
prioriti
activ
includ
improv
diagnost
vaccin
human
camel
well
basic
translat
research
serolog
assay
critic
evalu
efficaci
new
vaccin
patient
treatment
diagnost
tool
confirm
infect
perform
serosurveil
varieti
serolog
assay
develop
global
commerci
inhous
howev
evid
support
qualiti
perform
assay
consist
one
anoth
particip
intercountri
meet
merscov
cairo
egypt
june
recogn
issu
public
health
prioriti
call
studi
compar
current
avail
serolog
assay
therefor
assembl
panel
human
serum
plasma
polyclon
antibodi
compar
perform
serolog
assay
merscov
invit
particip
use
test
algorithm
diagnos
sampl
real
patient
sampl
assay
evalu
sensit
specif
pa
et
al
describ
impact
singl
intern
standard
would
reduc
interlaboratori
variabl
merscov
diagnost
albeit
case
nat
assay
end
includ
sampl
panel
exampl
potenti
intern
standard
materi
assess
effect
harmon
data
particip
laboratori
nation
institut
biolog
standard
control
nibsc
human
materi
advisori
committe
project
approv
project
ministri
health
oman
ministri
health
saudi
arabia
korea
nation
institut
health
south
korea
donat
convalesc
serum
plasma
sampl
pcrconfirm
merscovinfect
patient
patient
donor
gave
inform
consent
use
serum
plasma
sampl
anonym
treat
merscov
convalescentphas
serum
plasma
solvent
deterg
use
valid
method
ensur
residu
infecti
viru
store
studi
sampl
dispatch
ice
pack
particip
blind
code
studi
sampl
provid
particip
tabl
includ
plasma
sampl
sampl
individu
patient
sampl
smaller
serum
donat
pool
sampl
sampl
base
antibodi
titer
determin
use
recombiviru
human
merscov
nucleoprotein
np
antibodi
igg
elisa
kit
alpha
diagnost
intern
http
categor
sampl
high
medium
lowposit
pool
figur
includ
merscovneg
serum
antibodi
human
coronaviru
sampl
test
specif
assay
tabl
coauthor
mam
cd
precharacter
donat
sampl
purifi
human
mer
polyclon
antibodi
transchromosom
tc
cattl
immun
either
recombin
spike
protein
whole
inactiv
viru
sampl
donat
eddi
j
sullivan
sab
biotherapeut
inc
sioux
fall
sd
usa
dilut
materi
univers
buffer
mmoll
trishcl
ph
human
serum
albumin
trehalos
concentr
mgml
particip
laboratori
list
end
articl
locat
australia
china
mainland
hong
kong
germani
south
korea
netherland
unit
state
unit
kingdom
laboratori
particip
organ
includ
nation
control
laboratori
diagnost
laboratori
research
laboratori
particip
test
sampl
panel
use
routin
assay
merscov
serolog
ask
particip
perform
independ
assay
differ
day
provid
excel
spreadsheet
microsoft
http
wwwmicrosoftcom
report
raw
data
assay
interpret
result
posit
neg
diagnosi
sampl
combin
titer
rel
potenc
rel
titer
estim
unweight
geometr
mean
gm
sampl
laboratori
use
laboratori
gm
calcul
overal
unweight
gm
sampl
express
variabl
laboratori
use
geometr
coeffici
variat
gcv
sd
log
transform
estim
mitig
effect
potenti
outlier
calcul
robust
estim
use
r
packag
refer
particip
laboratori
code
number
randomli
alloc
laboratori
return
data
use
differ
assay
method
assay
result
separ
method
refer
accord
laboratori
number
assay
code
exampl
ppnt
pseudoparticl
neutral
test
tcid
tissu
cultur
infecti
dose
total
dataset
return
tabl
http
wwwnc
data
cover
rang
differ
assay
format
neutral
assay
elisa
immunofluoresc
test
microarray
gener
good
agreement
assay
test
studi
assay
quantit
measur
limit
detect
titer
sampl
vari
greatli
overal
determin
posit
neg
agre
assay
except
laboratori
tcid
mn
microneutr
fail
detect
posit
sampl
sampl
test
detect
posit
panel
neg
control
sampl
deem
neg
quantit
assay
instanc
laboratori
report
result
cutoff
sampl
assay
sampl
correctli
diagnos
neg
overal
test
algorithm
laboratori
detect
sampl
cutoff
dilut
assay
laboratori
detect
sampl
cutoff
dilut
assay
laboratori
detect
sampl
cutoff
dilut
test
particip
detect
pool
hightit
merscov
antibodi
pool
sampl
assay
tabl
detect
pool
b
mediumtit
pool
sampl
quantit
assay
tcid
mn
assay
laboratori
quantit
assay
particip
detect
high
pool
higher
titer
medium
pool
qualit
assay
assay
gave
borderlin
posit
equivoc
result
medium
pool
assay
euroimmun
elisa
http
wwweuroimmuncom
laboratori
inhous
immunofluoresc
assay
laboratori
lowposit
pool
pool
c
sampl
detect
posit
singl
assay
studi
alpha
diagnost
intern
mer
np
elisa
perform
laboratori
particip
score
posit
purifi
igg
sampl
merscovimmun
transchromosom
bovin
sampl
sampl
qualit
assay
quantit
assay
n
elisa
laboratori
alpha
diagnost
intern
mer
np
elisa
laboratori
unabl
detect
sampl
expect
np
assay
fail
detect
sampl
antibodi
rais
recombin
emerg
infecti
diseas
wwwcdcgoveid
vol
octob
mer
spike
protein
howev
surpris
assay
detect
sampl
antibodi
rais
whole
inactiv
viru
individu
convalescentphas
plasma
sampl
saw
variabl
result
compar
pool
materi
despit
sampl
sampl
correctli
identifi
posit
test
sampl
correctli
diagnos
posit
test
identifi
borderlin
posit
laboratori
euroimmun
elisa
assay
sampl
difficult
individu
patient
plasma
detect
posit
neg
tcid
mn
assay
laboratori
equivocalposit
inhous
immunofluoresc
assay
laboratori
euroimmun
elisa
borderlineneg
lab
equivoc
lab
weak
posit
lab
sampl
weakest
posit
individu
sampl
test
panel
saw
titer
quantit
assay
detect
posit
compil
result
quantit
assay
individu
posit
plasma
sampl
figur
simplifi
comparison
assay
report
result
differ
laboratori
rel
either
transchromosom
bovin
igg
sampl
rais
whole
inactiv
viru
sampl
highposit
pool
human
serum
pool
sampl
express
data
potenc
rel
either
chosen
potenti
refer
prepar
assign
arbitrari
valu
observ
improv
agreement
test
tabl
figur
saw
greatest
reduct
variat
laboratori
smaller
sem
figur
smaller
percentag
geometr
coeffici
variat
gcv
tabl
use
pool
human
serum
sampl
standard
transchromosom
bovin
igg
rais
whole
viru
sampl
show
substanti
improv
agreement
laboratori
howev
elisa
method
includ
studi
could
identifi
sampl
posit
detect
sporad
case
merscov
continu
develop
new
vaccin
combat
diseas
remain
import
serosurveil
understand
exposur
diseas
sever
ill
person
expos
viru
import
serolog
assay
diagnosi
mer
case
also
consid
guidelin
laboratori
test
merscov
updat
januari
specif
includ
sampl
collect
suspect
merscov
case
serolog
guidelin
list
situat
laboratori
conduct
serolog
test
merscov
defin
sporad
merscov
case
molecular
test
nucleic
acid
amplif
method
possibl
part
investig
ongo
outbreak
serolog
survey
retrospect
analysi
extent
outbreak
collabor
studi
evalu
perform
assay
detect
merscov
antibodi
use
panel
serolog
sampl
laboratori
correctli
identifi
neg
sampl
panel
includ
contain
antibodi
coronavirus
impli
good
specif
assay
laboratori
report
posit
result
correctli
except
sampl
test
neg
assay
howev
result
demonstr
import
test
algorithm
observ
instanc
sampl
incorrectli
determin
neg
borderlineequivoc
singl
test
singl
laboratori
tabl
howev
laboratori
use
test
algorithm
involv
method
analysi
sampl
sporad
spuriou
result
correctli
diagnos
posit
neg
use
singl
assay
type
would
found
higher
proport
incorrect
result
result
sampl
pool
serum
sampl
patient
confirm
merscov
highlight
lack
sensit
assay
studi
investig
would
need
determin
antibodi
titer
pool
limit
detect
assay
target
n
protein
import
understand
whether
specif
window
time
clinic
sampl
serolog
taken
whether
patient
mount
detect
antibodi
respons
spike
protein
infect
inform
may
lead
updat
guidelin
laboratori
test
merscov
raw
titer
report
laboratori
perform
quantit
assay
vari
greatli
sampl
laboratori
tabl
use
refer
materi
assay
tighten
valu
laboratori
sampl
enhanc
compar
figur
reduc
gcv
percentag
laboratori
tabl
perhap
unsurprisingli
magnitud
reduct
gcv
percentag
noteworthi
merscov
exampl
import
emerg
pathogen
potenti
caus
outbreak
diagnost
test
emerg
pathogen
often
develop
outbreak
without
proper
valid
calibr
studi
show
import
use
standard
reagent
allow
better
comparison
result
differ
laboratori
interpret
result
differ
studi
clinic
trial
continu
face
emerg
pathogen
pose
signific
risk
human
health
import
use
experi
gain
studi
improv
respons
next
threat
standard
assay
key
issu
differ
group
around
world
work
develop
produc
novel
assay
vaccin
product
need
standard
merscov
serolog
discuss
wide
support
whointern
vaccin
institut
joint
symposium
merscov
vaccin
develop
seoul
south
korea
june
sever
potenti
vaccin
develop
immun
respons
elicit
efficaci
correl
protect
must
assess
use
refer
intern
standard
enabl
worldwid
harmon
assay
compar
result
differ
preclin
clinic
studi
assess
specif
sensit
method
crucial
improv
understand
use
limit
serolog
assay
emerg
diseas
littl
knowledg
diseas
progress
antibodi
profil
key
inform
avail
infecti
diseas
